Unilever to introduce mouthwash that claims to kill 99.9% of coronavirus

Global FMCG chief Unilever said on Saturday that it would bring its mouthwash formulation to India, which it claims will reduce coronavirus by 99.9 percent after 30 seconds of rinsing.

The company said in a statement, “Unilever has confirmed that preliminary laboratory test results show that the mouthwash formulation containing CPC technology contains a 99.9 percent reduction of SARS-COV-2, the virus that causes COVID-19. Is made, after 30 seconds. ”

The virus that causes COVID-19 is mainly spread through salivary drops or nasal discharge, which has been found before, during and after the acute phase of the disease, as well as in asymptomatic cases. .

“Therefore, reducing viral load in the mouth may help reduce transmission. Findings indicate that mouthwash may become an important addition to other everyday safety measures such as handwashing, physical disturbances, and wearing masks. is.”

Unilever Oral Care Research and Development Head Glyn Roberts said, “While we are clear that this is not a cure or proven way to prevent the transmission of coronaviruses, our results are promising.”

Roberts said that given the critical phase of the epidemic, the company feels that it is important to share the results of the mouthwash.

The company said that the technology will be brought into the Pepsodent Germicheck Mouth Rinse Liquid by the hands of Hindustan Unilever Limited (HUL), Unilever, which will be launched in India in December 2020.

Unilever said that its mouthwash was tested using the cetylpyridinium chloride technique, conducted by Microback Laboratories, an independent and internationally recognized testing facility on behalf of Unilever Research Laboratories in the US.

CPC is a widely used cosmetic ingredient, also used by the dental industry, and is known for its antibacterial and anti-virus benefits.

The test was rinsed at both 30 and 60 seconds, aiming to replicate real-life use of mouthwash in an in-vitro context.

The company, however, stated, “The tests do not indicate that the formulation is a treatment for COVID-19, nor is it a guarantee that it will automatically stop transmission.

(Only the headline and picture of this report have been reworked by Business Standard employees; the rest of the content is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always worked hard to provide information and commentary on events that are of interest to you and have broad political and economic implications for the country and the world. Your encouragement and continued feedback on improving our offering has only strengthened our resolve and commitment to these ideals. Even during these difficult times arising from Kovid-19, we are committed to keeping you informed and updated with relevant news, official views and critical commentary on topical issues of relevance.
However, we have a request.

As we fight the economic impact of the epidemic, we need your support even more, so that we continue to provide you with more quality content. Our subscription model has seen enthusiastic response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of offering you better and more relevant content. We believe in free, fair and reliable journalism. Your support through greater membership can help us practice the journalism to which we are committed.

Support quality journalism and Subscribe to Business Standard.

Digital editor

Related Posts